
Matthias Ocker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1563495/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?. Expert Opinion on Investigational Drugs, 2022, 31, 221-233.	1.9	5
2	Pharmacologic Antagonization of Cannabinoid Receptor 1 Improves Cholestasis in Abcb4 Mice. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 1041-1055.	2.3	4
3	Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation. Cancers, 2022, 14, 1826.	1.7	23
4	Predicting the outcome of patients with hepatocellular carcinoma: new approaches beyond established clinical scoring systems. Expert Review of Gastroenterology and Hepatology, 2021, 15, 111-113.	1.4	1
5	Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers, 2021, 13, 1558.	1.7	8
6	Cannabinoid receptor 1 knockout alleviates hepatic steatosis by downregulating perilipin 2. Laboratory Investigation, 2020, 100, 454-465.	1.7	27
7	NF-κB Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients. Frontiers in Immunology, 2020, 11, 598444.	2.2	153
8	Dissecting the immune cell landscape in hepatocellular carcinoma—are we understanding complexity?. Annals of Translational Medicine, 2020, 8, 666-666.	0.7	2
9	Challenges and opportunities in drug development for nonalcoholic steatohepatitis. European Journal of Pharmacology, 2020, 870, 172913.	1.7	12
10	Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma. World Journal of Gastroenterology, 2020, 26, 279-290.	1.4	12
11	Systemic Therapy of Advanced Liver Cancer. , 2020, , 661-666.		Ο
12	Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncology, The, 2019, 20, 1454-1466.	5.1	125
13	Proteomics—a new approach to identify targets and biomarkers for hepatocellular carcinoma?. Biotarget, 2019, 3, 6-6.	0.5	Ο
14	The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications. International Journal of Molecular Sciences, 2019, 20, 5266.	1.8	39
15	Epigenetic Regulation of p21cip1/waf1 in Human Cancer. Cancers, 2019, 11, 1343.	1.7	22
16	First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity. European Journal of Cancer, 2019, 109, 103-110.	1.3	76
17	Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers, 2019, 11, 1987.	1.7	12
18	Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World Journal of Gastroenterology, 2019, 25, 3136-3150.	1.4	51

#	Article	IF	CITATIONS
19	You BETer be aware – learnings from a negative Phase 1 study. Oncotarget, 2019, 10, 3145-3146.	0.8	Ο
20	Abstract CT015: Phase I dose-escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer. , 2019, , .		1
21	Abstract CT015: Phase I dose-escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer. , 2019, , .		0
22	Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. Lung Cancer, 2018, 123, 14-21.	0.9	21
23	Biomarkers for hepatocellular carcinoma: What's new on the horizon?. World Journal of Gastroenterology, 2018, 24, 3974-3979.	1.4	34
24	Abstract A099: Safety, tolerability, pharmacokinetics, and efficacy of pan-fibroblast growth factor receptor inhibitor rogaratinib in Japanese patients with refractory, locally advanced metastatic solid tumors selected with a novel, mRNA-based patient selection strategy. , 2018, , .		1
25	Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. British Journal of Cancer, 2017, 116, 1505-1512.	2.9	25
26	Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer. Expert Opinion on Investigational Drugs, 2017, 26, 133-136.	1.9	11
27	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports, 2017, 21, 1953-1967.	2.9	117
28	Preclinical evaluation of the <scp>BET</scp> bromodomain inhibitor <scp>BAY</scp> 1238097 for the treatment of lymphoma. British Journal of Haematology, 2017, 178, 936-948.	1.2	42
29	Abstract 3738: Use of tumor mRNA expression for patient selection in a phase I study of the pan-fibroblast growth factor receptor inhibitor BAY 1163877. , 2017, , .		1
30	Patient selection using novel RNA-based approaches: Early experience from a phase I study with the pan-FGFR inhibitor BAY 1163877 in patients with urothelial bladder cancer Journal of Clinical Oncology, 2017, 35, 386-386.	0.8	5
31	Biliary tract cancer stem cells - translational options and challenges. World Journal of Gastroenterology, 2017, 23, 2470.	1.4	13
32	Fibromyalgia syndrome: metabolic and autophagic processes in intermittent cold stress mice. Pharmacology Research and Perspectives, 2016, 4, e00248.	1.1	13
33	In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers. Nuclear Medicine and Biology, 2016, 43, 27-34.	0.3	4
34	Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs. Expert Opinion on Therapeutic Targets, 2016, 20, 783-799.	1.5	50
35	Abstract 4703: The BET inhibitor BAY 1238097 shows efficacy in BRAF wild-type and mutant melanoma models. , 2016, , .		3
36	Abstract 4714:In vivoefficacy of BET inhibitor BAY 1238097 in preclinical models of melanoma and lung		2

cancer. , 2016, , .

#	Article	IF	CITATIONS
37	Morphological Alterations in Gastrocnemius and Soleus Muscles in Male and Female Mice in a Fibromyalgia Model. PLoS ONE, 2016, 11, e0151116.	1.1	25
38	The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget, 2016, 7, 745-758.	0.8	38
39	Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells. Oncotarget, 2016, 7, 20312-20323.	0.8	33
40	Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer. Oncotarget, 2016, 7, 28998-29010.	0.8	37
41	The panâ€deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Molecular Carcinogenesis, 2015, 54, 585-597.	1.3	26
42	The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression. International Journal of Oncology, 2015, 47, 963-970.	1.4	22
43	Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study. Oncology Reports, 2015, 34, 1549-1556.	1.2	20
44	Early to Phase II drugs currently under investigation for the treatment of liver fibrosis. Expert Opinion on Investigational Drugs, 2015, 24, 309-327.	1.9	25
45	Gallotannin is a DNA damaging compound that induces senescence independently of p53 and p21 in human colon cancer cells. Molecular Carcinogenesis, 2015, 54, 1037-1050.	1.3	12
46	lleal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex. Journal of Surgical Research, 2015, 194, 388-393.	0.8	10
47	Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models. Cancer Research, 2015, 75, 3524-3524.	0.4	4
48	Abstract 772: Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin. , 2015, , .		6
49	Abstract B76: Evaluation of the novel BET Bromodomain inhibitor BAY 1238097 in lymphoma models identifies EZH2 and MYD88 mutations as potential biomarkers and the bases for combinations. , 2015, , .		0
50	3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer. Anticancer Research, 2015, 35, 4697-705.	0.5	19
51	Pathological Impact of Hepatitis B Virus Surface Proteins on the Liver Is Associated with the Host Genetic Background. PLoS ONE, 2014, 9, e90608.	1.1	26
52	Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment. Current Signal Transduction Therapy, 2014, 9, 15-25.	0.3	4
53	Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer. Molecular and Cellular Biochemistry, 2014, 396, 257-268.	1.4	20
54	Heat dissipation after nonanatomical lung resection using a laser is mainly due to emission to the environment: an experimental ex vivo study. Lasers in Medical Science, 2014, 29, 1037-1042.	1.0	3

#	Article	IF	CITATIONS
55	The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas. Tumor Biology, 2014, 35, 8979-8989.	0.8	37
56	Abstract 1739: Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research, 2014, 74, 1739-1739.	0.4	8
57	Abstract CT209: A phase I study with the oral pan-CDK inhibitor BAY 1000394 in patients with advanced stage small cell lung or ovarian cancer. , 2014, , .		1
58	Epigenetics and pancreatic cancer: Pathophysiology and novel treatment aspects. World Journal of Gastroenterology, 2014, 20, 7830.	1.4	83
59	Abstract 900: Computing tumor growth rate across pre- and post-treatment periods uncovers anti-tumor activity in patients treated by a pan-CDK inhibitor (BAY1000394). , 2014, , .		Ο
60	Abstract 569: AKT1 (E17K) mutation: coexistence with oncogenic alterations, prevalence, and correlation to clinical parameter in a large series of breast cancer patients. , 2014, , .		1
61	Endoplasmic Reticulum Stress Plays a Pivotal Role in Cell Death Mediated by the Pan-Deacetylase Inhibitor Panobinostat in Human Hepatocellular Cancer Cells. Translational Oncology, 2013, 6, 143-IN6.	1.7	32
62	Rhenium Complexes with Visible‣ightâ€Induced Anticancer Activity. ChemMedChem, 2013, 8, 924-927.	1.6	74
63	Epidermal growth factor-induced modulation of cytokeratin expression levels influences the morphological phenotype of head and neck squamous cell carcinoma cells. Cell and Tissue Research, 2013, 351, 59-72.	1.5	10
64	GBP-1 acts as a tumor suppressor in colorectal cancer cells. Carcinogenesis, 2013, 34, 153-162.	1.3	85
65	Embryonic Transcription Factors CDX2 and Oct4 Are Overexpressed in Neuroendocrine Tumors of the Ileum: A Pilot Study. European Surgical Research, 2013, 51, 14-20.	0.6	3
66	The pan-deacetylase inhibitor panobinostat modulates the expression of epithelial-mesenchymal transition markers in hepatocellular carcinoma models. Oncology Letters, 2013, 5, 127-134.	0.8	22
67	Abstract 1521: Role of the guanylate-binding-protein 1 (GBP-1) in immunoediting of colorectal carcinoma , 2013, , .		Ο
68	Current Status of Therapeutic Targeting of Developmental Signalling Pathways in Oncology. Current Pharmaceutical Biotechnology, 2012, 13, 2184-2220.	0.9	29
69	Editorial (Hot Topic: Novel Aspects of Apoptosis Modulating Drugs). Current Pharmaceutical Biotechnology, 2012, 13, 2182-2183.	0.9	1
70	Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. International Journal of Oncology, 2012, 41, 2093-2102.	1.4	73
71	Association of stem cell marker expression pattern and survival in human biliary tract cancer. International Journal of Oncology, 2012, 41, 511-522.	1.4	12
72	Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. International Journal of Oncology, 2012, 40, 1659-67.	1.4	18

#	Article	IF	CITATIONS
73	PIM1 kinase as a target for cancer therapy. Expert Opinion on Investigational Drugs, 2012, 21, 425-436.	1.9	108
74	Galectins as Novel Targets for the Treatment of Malignant Gliomas. ACS Symposium Series, 2012, , 171-180.	0.5	0
75	DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 1300-1315.	2.2	68
76	Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines. BMC Cancer, 2012, 12, 386.	1.1	41
77	Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncology Reports, 2012, 28, 1077-1083.	1.2	34
78	Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells. International Journal of Oncology, 2012, 40, 1581-9.	1.4	13
79	Apoptosis-Modulating Drugs for Improved Cancer Therapy. European Surgical Research, 2012, 48, 111-120.	0.6	74
80	Combination of the Deacetylase Inhibitor Panobinostat and the Multi-Kinase Inhibitor Sorafenib for the Treatment of Metastatic Hepatocellular Carcinoma - Review of the Underlying Molecular Mechanisms and First Case Report. Journal of Cancer, 2012, 3, 158-165.	1.2	22
81	Influence of Five Potential Anticancer Drugs on Wnt Pathway and Cell Survival in Human Biliary Tract Cancer Cells. International Journal of Biological Sciences, 2012, 8, 15-29.	2.6	25
82	Dual anticancer activity in a single compound: visible-light-induced apoptosis by an antiangiogenic iridium complex. Chemical Communications, 2012, 48, 1863-1865.	2.2	103
83	Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Experimental Cell Research, 2012, 318, 1832-1843.	1.2	64
84	New Drugs, Old Fashioned Ways: ER Stress Induced Cell Death. Current Pharmaceutical Biotechnology, 2012, 13, 2228-2234.	0.9	17
85	Cannabinoid Receptor Type I Modulates Alcohol-Induced Liver Fibrosis. Molecular Medicine, 2011, 17, 1285-1294.	1.9	72
86	AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. International Journal of Oncology, 2011, 40, 876-88.	1.4	14
87	Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT. International Journal of Oncology, 2011, 39, 433-42.	1.4	10
88	Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 129-139.	1.4	105
89	Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: "To Be or Not to Be Acetylated�. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-15.	3.0	18
90	Influence of stress and health-behaviour on miRNA expression. Molecular Medicine Reports, 2010, 3, 455-7.	1.1	24

#	Article	IF	CITATIONS
91	Ru(η6-arene) complexes of combretastatin-analogous oxazoles with enhanced anti-tumoral impact. European Journal of Medicinal Chemistry, 2010, 45, 4890-4896.	2.6	22
92	Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 183-195.	2.2	240
93	Oxazoleâ€Bridged Combretastatinâ€A Analogues with Improved Anticancer Properties. ChemMedChem, 2010, 5, 420-427.	1.6	20
94	The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response. Hepatology, 2010, 51, 398-404.	3.6	113
95	Labeling and Glycosylation of Peptides Using Click Chemistry: A General Approach to ¹⁸ Fâ€Glycopeptides as Effective Imaging Probes for Positron Emission Tomography. Angewandte Chemie - International Edition, 2010, 49, 976-979.	7.2	109
96	Thymoquinone hydrazone derivatives cause cell cycle arrest in p53-competent colorectal cancer cells. Experimental and Therapeutic Medicine, 2010, 1, 369-375.	0.8	31
97	Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and proliferation. Photochemical and Photobiological Sciences, 2010, 9, 734-743.	1.6	31
98	The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cellular Oncology, 2010, 32, 285-300.	1.9	38
99	Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib. World Journal of Gastroenterology, 2010, 16, 3592.	1.4	7
100	Deacetylase inhibitors - focus on non-histone targets and effects. World Journal of Biological Chemistry, 2010, 1, 55.	1.7	55
101	Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. International Journal of Oncology, 2010, 36, 49-58.	3.9	16
102	Differential regulation of connective tissue growth factor in renal cells by histone deacetylase inhibitors. Journal of Cellular and Molecular Medicine, 2009, 13, 2353-2364.	1.6	22
103	Differentiation patterning of vascular smooth muscle cells (VSMC) in atherosclerosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 455, 171-185.	1.4	29
104	Activation of tumor-specific T lymphocytes after laser-induced thermotherapy in patients with colorectal liver metastases. Cancer Immunology, Immunotherapy, 2009, 58, 1557-1563.	2.0	26
105	The Expression Pattern of PDX-1, SHH, Patched and Gli-1 Is Associated with Pathological and Clinical Features in Human Pancreatic Cancer. Pancreatology, 2009, 9, 116-126.	0.5	41
106	Cellular plasticity of trans- and dedifferentiation markers in human hepatoma cells in vitro and in vivo. International Journal of Oncology, 2009, 35, 69-80.	1.4	17
107	Overview of major classes of plant-derived anticancer drugs. International Journal of Biomedical Science, 2009, 5, 1-11.	0.5	61
108	Biomarkers for novel targeted therapies of hepatocellular carcinoma. Histology and Histopathology, 2009, 24, 493-502.	0.5	6

#	Article	IF	CITATIONS
109	Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. Journal of Cellular and Molecular Medicine, 2008, 12, 330-342.	1.6	137
110	Differential diagnostic challenge of chronic neutrophilic leukemia in a patient with prolonged leukocytosis. Journal of Hematopathology, 2008, 1, 23-27.	0.2	7
111	Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. International Journal of Cancer, 2008, 123, 1269-1277.	2.3	87
112	Conjugates of the fungal cytotoxin illudin M with improved tumour specificity. Bioorganic and Medicinal Chemistry, 2008, 16, 8592-8597.	1.4	19
113	Thymoquinone Triggers Inactivation of the Stress Response Pathway Sensor <i>CHEK1</i> and Contributes to Apoptosis in Colorectal Cancer Cells. Cancer Research, 2008, 68, 5609-5618.	0.4	145
114	The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. International Journal of Oncology, 2008, 33, 733-42.	1.4	7
115	The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines. Oncology Reports, 2008, 20, 1249-56.	1.2	21
116	Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scandinavian Journal of Gastroenterology, 2007, 42, 103-116.	0.6	75
117	Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. International Journal of Oncology, 2007, 31, 1391.	1.4	6
118	The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. International Journal of Oncology, 2007, , .	1.4	11
119	Histone deacetylase inhibitors: Signalling towards p21cip1/waf1. International Journal of Biochemistry and Cell Biology, 2007, 39, 1367-1374.	1.2	245
120	bcl-2-specific siRNAs restore Gemcitabine sensitivity in human pancreatic cancer cells. Journal of Cellular and Molecular Medicine, 2007, 11, 349-361.	1.6	30
121	Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs: the Investigational Drugs Journal, 2007, 10, 557-61.	0.7	29
122	The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. International Journal of Oncology, 2007, 31, 567-76.	1.4	14
123	Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. International Journal of Oncology, 2007, 31, 1391-402.	1.4	7
124	Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1. Journal of Hepatology, 2006, 45, 370-376.	1.8	43
125	Gastrointestinal cancer - only a deregulation of stem cell differentiation? (Review). International Journal of Molecular Medicine, 2006, 17, 483.	1.8	8
126	Gastrointestinal cancer - only a deregulation of stem cell differentiation? (Review). International Journal of Molecular Medicine, 2006, 17, 483-9.	1.8	12

#	Article	IF	CITATIONS
127	The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. Journal of Cancer Research and Clinical Oncology, 2005, 131, 385-394.	1.2	70
128	Overexpression of MMP9 and Tissue Factor in Unstable Carotid Plaques Associated with Chlamydia pneumoniae, Inflammation, and Apoptosis. Annals of Vascular Surgery, 2005, 19, 310-319.	0.4	34
129	Different capabilities of morphological pattern formation and its association with the expression of differentiation markers in a xenograft model of human pancreatic cancer cell lines. Pancreatology, 2005, 5, 387-397.	0.5	22
130	Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy. World Journal of Gastroenterology, 2005, 11, 5521.	1.4	6
131	Potentiated anticancer effects on hepatoma cells by the retinoid adapalene. Cancer Letters, 2004, 208, 51-58.	3.2	19
132	The combination of tamoxifen and 9cis retinoic acid exerts overadditive anti-tumoral efficacy in rat hepatocellular carcinoma. Journal of Hepatology, 2004, 40, 952-956.	1.8	10
133	Integrin-mediated control of cell growth. Hepatology, 2003, 38, 289-291.	3.6	20
134	The synthetic retinoid adapalene inhibits proliferation and induces apoptosis in colorectal cancer cellsin vitro. International Journal of Cancer, 2003, 107, 453-459.	2.3	32
135	Inducibility of microsomal liver function may differentiate cirrhotic patients with maintained compared with severely compromised liver reserve. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 445-449.	1.4	17
136	Detection of Chlamydia pneumoniae but not of Helicobacter pylori in symptomatic atherosclerotic carotids associated with enhanced serum antibodies, inflammation and apoptosis rate. Atherosclerosis, 2003, 168, 153-162.	0.4	41
137	The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. Journal of Hepatology, 2002, 36, 233-240.	1.8	124
138	Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis?. Digestive Diseases and Sciences, 2002, 47, 2669-2673.	1.1	11
139	A quadruple therapy synergistically blocks proliferation and promotes apoptosis of hepatoma cells. Oncology Reports, 0, , .	1.2	2